
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Your AI-Trained Oncology Knowledge Connection!


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gary Steinberg, MD, discusses the role of patient counseling and surveillance when using the gemcitabine intravesical system for BCG-unresponsive NMIBC.

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.

Gary Steinberg, MD, discusses the clinical significance of the new FDA-approved gemcitabine intravesical system for BCG-unresponsive NMIBC.

Published: September 26th 2025 | Updated: